ProQR Reports Q1 Financial Results with Significant Revenue Decline
- Financial Performance: ProQR's Q1 GAAP EPS stands at -€0.13, indicating a decline compared to the previous year, which poses challenges to the company's profitability and is likely to negatively impact investor confidence.
- Significant Revenue Decline: The company reported revenue of €2.03M, down 55.1% year-over-year, reflecting weak product demand that could lead to future liquidity issues, affecting operations and R&D investments.
- Data Anticipation: ProQR is awaiting the release of AX-0810 data, which is crucial for the company's strategic direction and market performance, drawing significant attention from investors.
- Strategic Partnership: ProQR has formed a partnership with Ginkgo and established an advisory board as part of its AI strategy, aiming to enhance competitiveness through technological innovation; despite current financial challenges, this move may pave the way for future growth.
Trade with 70% Backtested Accuracy
Analyst Views on PRQR
About PRQR
About the author
ProQR Reports Q1 Financial Results with Significant Revenue Decline
- Financial Performance: ProQR's Q1 GAAP EPS stands at -€0.13, indicating a decline compared to the previous year, which poses challenges to the company's profitability and is likely to negatively impact investor confidence.
- Significant Revenue Decline: The company reported revenue of €2.03M, down 55.1% year-over-year, reflecting weak product demand that could lead to future liquidity issues, affecting operations and R&D investments.
- Data Anticipation: ProQR is awaiting the release of AX-0810 data, which is crucial for the company's strategic direction and market performance, drawing significant attention from investors.
- Strategic Partnership: ProQR has formed a partnership with Ginkgo and established an advisory board as part of its AI strategy, aiming to enhance competitiveness through technological innovation; despite current financial challenges, this move may pave the way for future growth.
ProQR Forms AI Advisory Board and Partners with Ginkgo Bioworks
- AI Strategy Partnership: ProQR Therapeutics announced the formation of an AI advisory board in collaboration with Ginkgo Bioworks, aiming to leverage artificial intelligence to enhance drug discovery efficiency on its RNA editing technology platform, Axiomer, which is expected to significantly accelerate the R&D process.
- Access to Technology Platform: Through the partnership with Ginkgo, ProQR will gain access to Ginkgo's Nebula, an autonomous lab with over 50 instruments, a move that will eliminate a key bottleneck in AI-enabled drug discovery, thereby enhancing overall R&D capabilities.
- Investment and Development: Ginkgo has made an undisclosed equity investment in ProQR, indicating confidence in ProQR's AI-driven drug discovery initiatives while providing financial support to expedite its R&D efforts.
- Clinical Data Expectations: ProQR plans to report initial clinical data from its inaugural AI-driven drug discovery program by the end of this year, with a clinical trial application expected in mid-2026, marking a significant advancement in its AI drug discovery efforts.
PROQR FORMS AI ADVISORY BOARD AND PARTNERS WITH GINKGO BIOWORKS
Partnership Announcement: ProQR has announced a partnership with Ginkgo BioWorks to enhance its research and development efforts.
Formation of Advisory Board: The collaboration will also involve the formation of an advisory board to guide the partnership's initiatives.
ProQR Reports FY 2025 Financial Highlights
- Earnings Per Share: ProQR reported a GAAP EPS of €0.40 for FY 2025, indicating a level of profitability despite financial challenges, reflecting ongoing investments in R&D and operations.
- Cash Position: As of December 31, 2025, ProQR held approximately €92.4 million in cash and cash equivalents, a significant decrease from €149.4 million in 2024, indicating increased cash outflows in operations and necessitating a focus on future cash management strategies.
- Operating Cash Usage: The net cash used in operating activities for FY 2025 was €52.8 million, up 44% from €36.4 million in 2024, highlighting pressure on operational expenditures that could impact future financial stability.
- R&D Investment Growth: R&D costs for 2025 were €44.7 million, a 23% increase from €36.4 million last year, demonstrating the company's commitment to technological innovation and product development despite high expenditures.
Butterfly Network and Citius Pharma Boost Biotech Activity in After-Hours Trading
Butterfly Network Update: Butterfly Network's shares rose 6.04% after announcing CEO Joseph DeVivo and Interim CFO Megan Carlson will participate in investor meetings at the Evercore Healthcare Conference on December 2, 2025, highlighting their handheld ultrasound technology.
Citius Pharmaceuticals Collaboration: Citius Pharmaceuticals saw a 7.90% increase in shares after announcing a collaboration with Verix to utilize its AI-powered Tovana platform for the U.S. commercialization of LYMPHIR, an FDA-approved immunotherapy for cutaneous T-cell lymphoma.
General Market Activity: ProQR Therapeutics, Perrigo Company, and Tempest Therapeutics also experienced share price increases, with Tempest announcing plans to acquire CAR-T programs to enhance its pipeline.
Other Stocks Performance: Iterum Therapeutics and Processa Pharmaceuticals had minor share price movements without any new updates, reflecting varied investor sentiment in the biotech sector.
VTYX, MEDP, INBX Surge in After-Hours Trading Following Important Announcements
Ventyx Biosciences Surge: Ventyx Biosciences' shares skyrocketed over 88% after positive Phase 2 trial results for its obesity and cardiovascular risk treatment, VTX3232.
Medpace Holdings Performance: Medpace Holdings saw an 18% increase in shares following better-than-expected Q3 results and an updated fiscal year 2025 guidance.
Inhibrx Biosciences Update: Inhibrx Biosciences' shares rose over 10% as the company announced a live webcast to present topline results from its ChonDRAgon study on ozekibart for chondrosarcoma.
Other Notable Movers: Several biotech stocks, including Acumen Pharmaceuticals and SCYNEXIS, experienced significant after-hours gains, reflecting a broader positive trend in the sector.
ProQR Reports Q1 Financial Results with Significant Revenue Decline
- Financial Performance: ProQR's Q1 GAAP EPS stands at -€0.13, indicating a decline compared to the previous year, which poses challenges to the company's profitability and is likely to negatively impact investor confidence.
- Significant Revenue Decline: The company reported revenue of €2.03M, down 55.1% year-over-year, reflecting weak product demand that could lead to future liquidity issues, affecting operations and R&D investments.
- Data Anticipation: ProQR is awaiting the release of AX-0810 data, which is crucial for the company's strategic direction and market performance, drawing significant attention from investors.
- Strategic Partnership: ProQR has formed a partnership with Ginkgo and established an advisory board as part of its AI strategy, aiming to enhance competitiveness through technological innovation; despite current financial challenges, this move may pave the way for future growth.
ProQR Forms AI Advisory Board and Partners with Ginkgo Bioworks
- AI Strategy Partnership: ProQR Therapeutics announced the formation of an AI advisory board in collaboration with Ginkgo Bioworks, aiming to leverage artificial intelligence to enhance drug discovery efficiency on its RNA editing technology platform, Axiomer, which is expected to significantly accelerate the R&D process.
- Access to Technology Platform: Through the partnership with Ginkgo, ProQR will gain access to Ginkgo's Nebula, an autonomous lab with over 50 instruments, a move that will eliminate a key bottleneck in AI-enabled drug discovery, thereby enhancing overall R&D capabilities.
- Investment and Development: Ginkgo has made an undisclosed equity investment in ProQR, indicating confidence in ProQR's AI-driven drug discovery initiatives while providing financial support to expedite its R&D efforts.
- Clinical Data Expectations: ProQR plans to report initial clinical data from its inaugural AI-driven drug discovery program by the end of this year, with a clinical trial application expected in mid-2026, marking a significant advancement in its AI drug discovery efforts.
PROQR FORMS AI ADVISORY BOARD AND PARTNERS WITH GINKGO BIOWORKS
Partnership Announcement: ProQR has announced a partnership with Ginkgo BioWorks to enhance its research and development efforts.
Formation of Advisory Board: The collaboration will also involve the formation of an advisory board to guide the partnership's initiatives.
ProQR Reports FY 2025 Financial Highlights
- Earnings Per Share: ProQR reported a GAAP EPS of €0.40 for FY 2025, indicating a level of profitability despite financial challenges, reflecting ongoing investments in R&D and operations.
- Cash Position: As of December 31, 2025, ProQR held approximately €92.4 million in cash and cash equivalents, a significant decrease from €149.4 million in 2024, indicating increased cash outflows in operations and necessitating a focus on future cash management strategies.
- Operating Cash Usage: The net cash used in operating activities for FY 2025 was €52.8 million, up 44% from €36.4 million in 2024, highlighting pressure on operational expenditures that could impact future financial stability.
- R&D Investment Growth: R&D costs for 2025 were €44.7 million, a 23% increase from €36.4 million last year, demonstrating the company's commitment to technological innovation and product development despite high expenditures.
Butterfly Network and Citius Pharma Boost Biotech Activity in After-Hours Trading
Butterfly Network Update: Butterfly Network's shares rose 6.04% after announcing CEO Joseph DeVivo and Interim CFO Megan Carlson will participate in investor meetings at the Evercore Healthcare Conference on December 2, 2025, highlighting their handheld ultrasound technology.
Citius Pharmaceuticals Collaboration: Citius Pharmaceuticals saw a 7.90% increase in shares after announcing a collaboration with Verix to utilize its AI-powered Tovana platform for the U.S. commercialization of LYMPHIR, an FDA-approved immunotherapy for cutaneous T-cell lymphoma.
General Market Activity: ProQR Therapeutics, Perrigo Company, and Tempest Therapeutics also experienced share price increases, with Tempest announcing plans to acquire CAR-T programs to enhance its pipeline.
Other Stocks Performance: Iterum Therapeutics and Processa Pharmaceuticals had minor share price movements without any new updates, reflecting varied investor sentiment in the biotech sector.
VTYX, MEDP, INBX Surge in After-Hours Trading Following Important Announcements
Ventyx Biosciences Surge: Ventyx Biosciences' shares skyrocketed over 88% after positive Phase 2 trial results for its obesity and cardiovascular risk treatment, VTX3232.
Medpace Holdings Performance: Medpace Holdings saw an 18% increase in shares following better-than-expected Q3 results and an updated fiscal year 2025 guidance.
Inhibrx Biosciences Update: Inhibrx Biosciences' shares rose over 10% as the company announced a live webcast to present topline results from its ChonDRAgon study on ozekibart for chondrosarcoma.
Other Notable Movers: Several biotech stocks, including Acumen Pharmaceuticals and SCYNEXIS, experienced significant after-hours gains, reflecting a broader positive trend in the sector.
